StreetInsider.com  Oct 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+EMA+Panel+Says+Not+Enough+Evidence+for+Lower+Dosing+of+ARIAD+Pharma%27s+%28ARIA%29+Iclusig/9902006.html for the full story.
FierceBiotech  Oct 7  Comment 
Bellicum Pharmaceuticals has switched up its deal with Ariad Pharmaceuticals, agreeing to hand over $50 million for a no-strings-attached license to some cell-signaling technology.
GenEng News  Oct 6  Comment 
Ariad Pharmaceuticals is restructuring a license agreement made with Bellicum Pharmaceuticals for Ariad's cell-signaling technology. Per the revised deal, Bellicum is giving Ariad $50 million in three installments—$15 million upon signing of the...
SeekingAlpha  Oct 5  Comment 
By Mark Romero: What Has Changed Since The Beginning of the Year & Why Has This Stock Become Painful for Investors? Earlier in the year I wrote an article 'Why Now Is The Time To Buy Ariad Pharmaceuticals' and highlighted the potential of...
Motley Fool  Oct 2  Comment 
Ariad Pharmaceuticals stock is among today's top gainers after the Food and Drug Administration divvies a prized designation one of Ariad's pipeline products.
Benzinga  Oct 2  Comment 
Esperion Therapeutics (NASDAQ: ESPR) shares jumped 29.89% to $31.72 in pre-market trading after the company announced positive top-line Phase 2b results for ETC-1002. RealD (NYSE: RLD) shares jumped 20.60% to $11.30 in pre-market trading after...
StreetInsider.com  Oct 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Reports+AP26113+Receives+FDA+Breakthrough+Therapy+Designation/9879212.html for the full story.
StreetInsider.com  Sep 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Presents+Updated+Results+from+AP26113+in+NSCLC/9865913.html for the full story.
Benzinga  Sep 29  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial....
StreetInsider.com  Sep 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/ARIAD+Pharma+%28ARIA%29+Director+Whelan+Resigns%3B+Will+CEO+Berger+be+Next%3F/9847190.html for the full story.


Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki